Stockscreener 앱 받기
41.64
3.24%
-1.46
전일 마감가:
$43.10
열려 있는:
$42.58
하루 거래량:
1.55M
Relative Volume:
0.71
시가총액:
$5.05B
수익:
$692.26M
순이익/손실:
$-512.41M
주가수익비율:
-9.8208
EPS:
-4.24
순현금흐름:
$-274.36M
1주 성능:
+3.82%
1개월 성능:
-11.23%
6개월 성능:
+55.67%
1년 성능:
+119.50%
1일 변동 폭
$39.72
$42.86
1주일 범위
$34.88
$45.00
52주 변동 폭
$15.81
$50.89
가든트헬스 Stock (GH) Company Profile
명칭
Guardant Health Inc
전화
855-698-8887
주소
3100 HANOVER STREET, PALO ALTO
GH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
41.71 | 5.05B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
512.75 | 194.04B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
204.46 | 146.36B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
118.00 | 33.96B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
407.98 | 33.45B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
182.61 | 32.16B | 15.41B | 1.37B | 2.11B | 7.50 |
가든트헬스 Stock (GH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-28 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-24 | 재개 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-09-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-11-01 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | 개시 | Craig Hallum | Buy |
| 2022-10-06 | 개시 | Stephens | Overweight |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Overweight |
| 2022-04-28 | 재개 | BTIG Research | Buy |
| 2022-02-24 | 재확인 | Canaccord Genuity | Buy |
| 2022-02-24 | 재확인 | Citigroup | Buy |
| 2022-02-24 | 재확인 | Cowen | Outperform |
| 2022-02-24 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-24 | 재확인 | SVB Leerink | Outperform |
| 2022-02-24 | 재확인 | Stifel | Buy |
| 2022-02-24 | 재확인 | Wells Fargo | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-11 | 개시 | Stifel | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-06-12 | 개시 | BTIG Research | Buy |
| 2020-02-21 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-08-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-04-16 | 개시 | Canaccord Genuity | Buy |
| 2019-04-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | 재확인 | BofA/Merrill | Neutral |
| 2018-10-29 | 개시 | BofA/Merrill | Neutral |
| 2018-10-29 | 개시 | JP Morgan | Overweight |
| 2018-10-29 | 개시 | William Blair | Outperform |
모두보기
가든트헬스 주식(GH)의 최신 뉴스
Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation - Seeking Alpha
Guardant Health rises after Medicare ADLT status for colorectal cancer test - MSN
Guardant Health at Barclays Conference: Strategic Expansion in Diagnostics By Investing.com - Investing.com UK
Guardant Health’s ADLT Status Boosts Shield CRC Test’s Market Position and Financial Outlook - TipRanks
1,415 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by SBI Securities Co. Ltd. - Defense World
Investing in Guardant Health (NASDAQ:GH) a year ago would have delivered you a 129% gain - Simply Wall St
Raymond James maintains Guardant Health stock at Outperform By Investing.com - Investing.com Canada
Guardant Health gains ADLT status for CRC blood test By Investing.com - Investing.com Canada
Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue - Benzinga
Sector Update: Health Care - TradingView
Guardant Health stock up on Medicare ADLT status (GH:NASDAQ) - Seeking Alpha
Guardant Health Shares Soar After Colorectal Cancer Test Granted ADLT Status -March 11, 2025 at 11:01 am EDT - Marketscreener.com
Citi maintains Buy on Guardant Health, price target at $60 By Investing.com - Investing.com UK
Guardant Health Receives ADLT Status From CMS for Shield Blood Test - 01Net
Guardant Health Says Colorectal Cancer Test Granted ADLT Status -March 11, 2025 at 08:48 am EDT - Marketscreener.com
Guardant Health gains ADLT status for CRC blood test - Investing.com India
Guardant Health Receives ADLT Status From CMS For Shield Blood Test -March 11, 2025 at 07:19 am EDT - Marketscreener.com
When the Price of (GH) Talks, People Listen - Stock Traders Daily
FDA approves blood test for colon cancer detection - MSN
Bank of New York Mellon Corp Reduces Stock Holdings in Guardant Health, Inc. (NASDAQ:GH) - Defense World
Morgan Stanley Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock - Defense World
Principal Financial Group Inc. Has $308,000 Stake in Guardant Health, Inc. (NASDAQ:GH) - Defense World
Guardant Health Base Business in 'Fundamentally Good Shape,' Morgan Stanley Says - Marketscreener.com
Cancer Biomarkers Research Report 2024: Global Market Projected to Soar to USD 62.14 Billion by 2034, Driven by Technological Advancements and Increasing Demand for Early Detection - GlobeNewswire Inc.
Guardant Health, Inc. (NASDAQ:GH) Short Interest Update - Defense World
Lung Cancer Diagnostics Market Growth | Trends, Size & Forecast 2025-2033 | DSS Imagetec, Abbott, Guardant Health. - openPR
Guardant Health director Joyce sells $4,271 in stock - Investing.com
Morgan Stanley raises Guardant Health target to $52, maintains Overweight - Investing.com India
Guardant Health director Joyce sells $4,271 in stock By Investing.com - Investing.com UK
Guardant Health price target raised to $52 from $42 at Morgan Stanley - TipRanks
LSUHS partners with Dak Prescott to boost colon cancer screening - KTALnews.com
Morgan Stanley raises Guardant Health target to $52, maintains Overweight By Investing.com - Investing.com UK
Morgan Stanley Adjusts Price Target on Guardant Health to $52 From $42, Keeps Overweight Rating - Marketscreener.com
Guardant Health at TD Cowen Conference: Strategic Growth and Challenges By Investing.com - Investing.com UK
Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities - The Bakersfield Californian
Commit To Buy Guardant Health At $32, Earn 17.9% Annualized Using Options - Nasdaq
Guardant Health Financial Report: Q4 2024 Revenue Surpasses ExpectationsNews and Statistics - IndexBox, Inc.
Guardant Health’s (NASDAQ:GH) Q4: Beats On Revenue - Yahoo Finance
Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of “Buy” by Analysts - Defense World
ARK Investment Management LLC Has $43.99 Million Stock Position in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health (NASDAQ:GH) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Rhumbline Advisers Buys 3,529 Shares of Guardant Health, Inc. (NASDAQ:GH) - Defense World
(GH) Technical Data - Stock Traders Daily
New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change - Yahoo Finance
Guardant Health (NASDAQ:GH) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
Guardant Health (GH): Among the Best Performing Mid Cap Stocks to Buy According to Analysts - Insider Monkey
Guardant Health Stock Surges Amid Analyst Optimism - TipRanks
Is Guardant Health (GH) Outperforming Other Medical Stocks This Year? - MSN
Guardant Health (NASDAQ:GH) Stock Price Down 6.9% Following Weak Earnings - MarketBeat
가든트헬스 (GH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
가든트헬스 주식 (GH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Joyce Meghan V. | Director |
Mar 03 '25 |
Sale |
42.71 |
100 |
4,271 |
7,647 |
| Saia John G. | Chief Legal Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
5,949 |
0 |
40,650 |
| Monroe Terilyn J. | Chief People Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
14,894 |
0 |
26,822 |
| Kalia Kumud | Chief Information Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
4,406 |
0 |
24,401 |
| Freeman Chris | Chief Commercial Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
5,686 |
0 |
40,355 |
| EAGLE CRAIG | Chief Medical Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
5,686 |
0 |
31,642 |
| Chudova Darya | Chief Technology Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
6,001 |
0 |
76,065 |
| Bell Michael Brian | Chief Financial Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
7,108 |
0 |
40,285 |
| Krognes Steve E. | Director |
Feb 28 '25 |
Option Exercise |
0.00 |
154 |
0 |
10,528 |
1.01%
0.88%
자본화:
|
볼륨(24시간):